South Texas hospitals get dedicated Nuwellis team for fluid care The move targets large hospital systems and cardiac programs, giving clinicians more direct support as they evaluate Aquadex therapy in the region.

#NUWE Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory

www.stocktitan.net/news/NUWE/nuwellis-stren...

Half of Nuwellis U.S. revenue now comes from pediatric care Now used at 47 pediatric centers, including six top-10 children’s hospitals, Aquadex is becoming a bigger growth driver as specialty-center adoption expands.

#NUWE Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

www.stocktitan.net/news/NUWE/nuwellis-pedia...

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and

#NUWE Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/NUWE/nuwellis-inc-a...

Nuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal Therapy Nuwellis (Nasdaq: NUWE) announced that the U.S. Patent and Trademark Office issued a new U.S. patent tied to U.S. Patent Application No. 18/298,810 on January 6, 2026.The patent covers advanced safety mechanisms for blood return line clamps in extracorporeal blood filtration systems, with specific relevance to pediatric extracorporeal therapy and the Vivian™ Pediatric CRRT System currently in development. Nuwellis said the invention aims to improve reliability and consistency of blood flow control, support stable system performance for small patient volumes, and strengthen the company’s pediatric intellectual property portfolio and cardio-renal strategy.

#NUWE Nuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal Therapy

www.stocktitan.net/news/NUWE/nuwellis-annou...

Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings Nuwellis (Nasdaq: NUWE) announced real-world data from Lenox Hill Hospital presented at ASN Kidney Week 2025 showing Aquadex ultrafiltration used across critical-care indications including oliguric AKI, post-cardiac-surgery volume overload, and pre-operative ESRD optimization.The retrospective review of 69 cases (2018–2024) reported an average 6.4 liters removed per patient over a mean 78 hours with stable hemodynamics, including patients on vasopressors, supporting broader clinical utility of precision ultrafiltration.

#NUWE Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings

www.stocktitan.net/news/NUWE/lenox-hill-hos...

Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S. Nuwellis (Nasdaq: NUWE) announced that a leading children’s hospital in the Northeast U.S. has initiated an Aquadex Ultrafiltration Program on Dec. 4, 2025. Pediatric nephrology and cardiology teams are adopting Aquadex for its minimal extracorporeal volume and real-time hematocrit monitoring to manage fluid-sensitive, high-acuity pediatric patients.The company says Aquadex usage is expanding across leading children’s hospitals nationwide and is being integrated into care pathways for complex cardiac, cardio-renal, and critical care cases, supporting Nuwellis’ pediatric growth strategy.

#NUWE Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.

www.stocktitan.net/news/NUWE/nuwellis-conti...

Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients

#NUWE Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum

www.stocktitan.net/news/NUWE/nuwellis-repor...

NUWE - Nuwellis Inc Latest Stock News & Market Updates Nuwellis Inc (NUWE) news hub: Track official press releases, clinical updates, and product developments in ultrafiltration therapy and renal monitoring technology.

#NUWE Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum

www.stocktitan.net/news/NUWE/nuwellis-repor...

Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian™ Pediatric System with Advanced Clamp Safety Technology Nuwellis (Nasdaq: NUWE) announced a notice of allowance from the U.S. Patent and Trademark Office dated Nov 10, 2025 for a patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtration systems, including the Vivian Pediatric CRRT System in development.The technology dynamically adjusts clamping force, reconditions tubing under defined thermal conditions, and adds thermal insulation to improve material stability. This patent supplements a Sept 2025 patent for hemolysis sensing and complements NIH grant-funded research and Aquadex pediatric use data to inform Vivian design.

#NUWE Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian™ Pediatric System with Advanced Clamp Safety Technology

www.stocktitan.net/news/NUWE/nuwellis-recei...

Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex® Nuwellis (Nasdaq: NUWE) announced groundbreaking results from their ULTRA-Peds registry study evaluating the Aquadex System in pediatric patients with kidney conditions. The multi-center study, involving 91 pediatric patients across 8 U.S. centers, demonstrated remarkable outcomes with a 92% survival rate during treatment and 66% survival to hospital discharge.The study included patients with congenital heart disease (30%), end-stage renal disease (25%), and malignancy (14%). The Aquadex therapy showed strong procedural success, with 86% of circuits completing treatment without interruption. Building on these results, Nuwellis is developing Vivian, a dedicated pediatric CRRT system for infants weighing 2.5-20kg, supported by a $3 million NIH grant.

#NUWE Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®

www.stocktitan.net/news/NUWE/nuwellis-annou...

Revolutionary Blood Safety Patent: Nuwellis's Vivian Device Could Transform Pediatric Care Medical device maker Nuwellis receives US Patent 12,415,021 for hemolysis detection in blood filtration systems, enhancing safety for pediatric patients using Vivian ultrafiltration device.

#NUWE Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration

www.stocktitan.net/news/NUWE/nuwellis-recei...

$3M NIH Grant Accelerates Development of Life-Saving Kidney Device for Children Under 20kg NIH awards $3M grant to Nuwellis' partner KBT to advance Vivian™, a pediatric continuous renal replacement therapy device for patients under 20kg, enhancing company's medical portfolio.

#NUWE Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

www.stocktitan.net/news/NUWE/nuwellis-inc-p...

Revolutionary Pediatric Kidney Device for 2.5kg Babies: Nuwellis Wins $3M NIH Grant for Breakthrough Tech Nuwellis advances Vivian™ pediatric CRRT device for patients under 20kg, addressing critical care gap. NIH grant supports FDA study of 15 patients. Builds on Aquadex SmartFlow® platform.

#NUWE Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio

www.stocktitan.net/news/NUWE/nuwellis-vivia...

(NASDAQ: #NUWE)
#Nuwellis_Inc is launching a new 24‑hour Aquadex circuit this fall—tailored for outpatient, same‑day fluid removal. This addition streamlines hospital workflows, boosts efficiency, and enhances patient convenience.
prismmarketview.com/nuwellis-lau...

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management Nuwellis (NASDAQ:NUWE) announced the upcoming launch of a new 24-hour circuit for Aquadex therapy in the United States this fall. This addition complements their existing 72-hour circuit option, enabling hospitals to better match supply with care settings while maintaining consistent therapy delivery.The new circuit is specifically designed for single-day outpatient sessions, supporting hospitals in building outpatient Aquadex programs that deliver scheduled fluid removal treatment without requiring hospital admission. The innovation aims to streamline clinic operations, enhance scheduling efficiency, and increase treatment capacity while providing patients with convenient same-day visits.

#NUWE Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

www.stocktitan.net/news/NUWE/nuwellis-intro...

Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter Nuwellis (Nasdaq: NUWE) has received FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). The catheter, available in 11 cm and 15 cm lengths, is designed for peripheral venous access to support ultrafiltration therapy with the Aquadex system for up to 72 hours.The clearance advances Nuwellis' strategy to build a comprehensive fluid management platform across various care settings, from ICU to outpatient facilities. The dELC features coil reinforcement and dual-lumen design for consistent blood flow, supporting the company's focus on three growth areas: critical care, cardiac surgery recovery, and hospital-based outpatient heart failure programs.

#NUWE Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter

www.stocktitan.net/news/NUWE/nuwellis-recei...

Critical Care Tech Expansion: Nuwellis Plans Acquisition of Rendiatech's Real-Time Kidney Monitoring System Medical tech company Nuwellis signs LOI to acquire Rendiatech, adding FDA-cleared Clarity RMS monitoring system to portfolio. Deal targets Q4 2025 close, addresses 20-50% ICU AKI incidence.

#NUWE Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company

www.stocktitan.net/news/NUWE/nuwellis-signs...

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights Nuwellis (Nasdaq: NUWE) reported Q2 2025 financial results, with revenue declining to $1.7 million from $2.2 million in Q2 2024, primarily due to industry-wide sterilization vendor issues. The company's gross margin contracted to 55.5% from 67.2% year-over-year.Key developments include expanding to 47 pediatric centers, completing a $5 million gross capital raise, and executing a manufacturing outsourcing plan to KDI Precision Manufacturing. The company reported a net loss of $12.6 million, or $60.99 per share, compared to $7.7 million loss in Q2 2024. As of June 30, 2025, Nuwellis maintained $4.5 million in cash and remained debt-free.

#NUWE Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/NUWE/nuwellis-inc-r...

Nuwellis Strategic Pivot: Company Doubles Down on U.S. Market After Exiting International Operations Medical tech company shifts focus to high-growth U.S. cardiac surgery and pediatric markets. Strategic realignment targets hospital-based outpatient expansion. Learn more.

#NUWE Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

www.stocktitan.net/news/NUWE/nuwellis-to-ex...

News; ( NASDAQ: #NUWE ) Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow System Under New CMS Code

Nuwellis Expands Aquadex Treatment to Outpatient Setting with 4x Higher Reimbursement Rate First successful outpatient fluid management treatment marks expansion milestone. New CMS rate increases from $413 to $1,639 per day. See growth potential.

#NUWE Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code

www.stocktitan.net/news/NUWE/nuwellis-annou...

Nuwellis Shareholders Green Light Major Changes: 70-to-1 Reverse Split and 100M Additional Shares Approved Stockholders back three key proposals including warrant exercise, share increase to 200M, and potential 1:70 reverse split. See what's next for Nuwellis.

#NUWE Nuwellis Stockholders Approve All Proposals at Special Meeting

www.stocktitan.net/news/NUWE/nuwellis-stock...

Exclusive: Nuwellis CEO Reveals Personal Journey and Strategic Roadmap in Candid Investor Interview Watch Nuwellis CEO John Erb discuss his leadership journey, development pipeline, and strategic vision in an exclusive on-demand investor presentation. Access now.

#NUWE Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

www.stocktitan.net/news/NUWE/nuwellis-parti...

🚀 Exciting times for #NUWE! With a new U.S. patent and CEO John Erb's return, investor confidence is soaring. Bullish momentum is strong, but watch for short-term consolidation. Consider going long at $14.50, targeting $16 & $17.50. Stay sharp! 📈 #Stocks #FeetrAI

🚀 Exciting times for #NUWE! With a new U.S. patent and CEO John Erb's return, investor optimism is soaring. Strong upward momentum and bullish indicators suggest potential gains. Consider a LONG position at $14.50, targeting $16 & $18. Stay sharp on market trends! 📈 #Stocks #Investing

🚀 Exciting times for #NUWE! With a new U.S. patent and the return of its veteran CEO, investor confidence is soaring. Bullish momentum is strong, but watch for volatility after a reverse split. Entry at $14.80, targets at $18 & $20. High-risk, high-reward! 📈 #Stocks #FeetrAI

🚀 Exciting times for #NUWE! With a new U.S. patent and CEO John Erb's return, investor optimism is soaring. 📈 RSI at 70.74 signals overbought, but MACD shows bullish momentum. Consider entry at $14.50, targeting $17 & $19. Caution: volatility ahead! #Stocks #FeetrAI

Just In: ( NASDAQ: #NUWE ) Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care Nuwellis (NASDAQ:NUWE) announced the termination of its REVERSE-HF clinical trial, which was evaluating ultrafiltration versus IV loop diuretic therapy for fluid management in hospitalized heart failure patients. The company will redirect its focus toward outpatient heart failure care, pediatric, and critical care markets.The trial, which began in 2022, had enrolled 167 patients before termination. This strategic decision is expected to save $4.0 million over 2.5 years. The company plans to analyze existing data for potential clinical publications. Importantly, the termination was not due to device performance or safety concerns, and the Nuwellis SmartFlow® remains FDA-cleared for fluid overload treatment.

#NUWE Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

www.stocktitan.net/news/NUWE/nuwellis-annou...